Management of Active Epistaxis with Nasal Sprays

First‑Line Pharmacologic Therapy

Oxymetazoline 0.05 % nasal spray is recommended as the first‑line treatment for active nosebleeds; when combined with firm compression of the soft lower third of the nose for 5–10 minutes, it achieves hemostasis in approximately 65–75 % of cases. (American Academy of Otolaryngology–Head and Neck Surgery guideline, strong recommendation) 1
The American Academy of Otolaryngology–Head and Neck Surgery (AAO‑HNS) guidelines (2020) endorse oxymetazoline as the preferred initial therapy based on established evidence. (AAO‑HNS, strong recommendation) 2

Phenylephrine nasal spray provides efficacy comparable to oxymetazoline for stopping active epistaxis and may be used when oxymetazoline is unavailable. (AAO‑HNS, moderate recommendation) 1
Epinephrine and cocaine nasal preparations can also produce vasoconstriction but require medical supervision and are not available without a prescription. (AAO‑HNS, conditional recommendation) 2

Recent prospective studies show that topical TXA achieves hemostasis in about 78 % of patients, markedly higher than the 35 % success rate observed with oxymetazoline under the same compression protocol. (AAO‑HNS, moderate‑quality evidence) 3
The AAO‑HNS notes that the TXA data are of moderate quality and derived mainly from studies conducted in a single geographic region; therefore, additional high‑quality, diverse research is required before TXA can be adopted as a first‑line option. (AAO‑HNS, moderate‑quality evidence) 4

Oxymetazoline should not be used for more than 3–5 consecutive days to avoid rhinitis medicamentosa (rebound congestion) and mucosal injury that can precipitate recurrent bleeding. (AAO‑HNS, moderate recommendation) 3
Use oxymetazoline with extreme caution—or avoid it—in patients with uncontrolled hypertension, because systemic vasoconstriction may exacerbate cardiovascular risk. (AAO‑HNS, strong caution) 1
Patients with known cardiovascular disease should also be managed cautiously when using oxymetazoline, due to potential systemic vasoconstrictive effects. (AAO‑HNS, strong caution) 1
Individuals with glaucoma require careful consideration before oxymetazoline use, given the risk of increased intra‑ocular pressure from systemic vasoconstriction. (AAO‑HNS, strong caution) 3

After bleeding stops, switching to a saline nasal spray or gel applied 2–4 times daily helps prevent recurrent epistaxis in up to 65 % of patients. (AAO‑HNS, moderate recommendation) 5
While moisturizers do not stop active bleeding, their routine use after hemostasis is essential for reducing the likelihood of rebleeding. (AAO‑HNS, moderate recommendation) 1

If bleeding persists despite two cycles of oxymetazoline spray plus compression, or if the bleeding is severe or life‑threatening, patients should be evaluated emergently. (AAO‑HNS, strong recommendation) 5
When vasoconstrictor therapy and compression fail, clinicians should consider nasal packing or cautery to achieve definitive hemostasis. (AAO‑HNS, strong recommendation) 1

The 2020 AAO‑HNS clinical practice guideline designates oxymetazoline 0.05 % nasal spray, combined with proper compression technique, as the most accessible and evidence‑supported first‑line treatment for active epistaxis. (AAO‑HNS, strong recommendation) 6
Although topical TXA shows promising superiority in early trials, the guideline currently recommends awaiting further high‑quality studies before revising the first‑line recommendation. (AAO‑HNS, moderate‑quality evidence) 3

The American Academy of Otolaryngology‑Head and Neck Surgery recommends oxymetazoline 0.05 % as the first‑line medication for acute epistaxis, achieving bleeding control in 65–75 % of cases. 7

In patients with active nosebleed, blow the nose first to clear clots and allow the medication to reach the bleeding site. 7
Apply oxymetazoline 0.05 % as two sprays directly to the bleeding nostril. 7
Immediately compress the soft lower third of the nose firmly for 5–10 minutes without checking for cessation. 7
Lean forward during compression to prevent blood from flowing down the throat. 7
If bleeding persists after the initial 5 minutes, repeat the spray‑and‑compression sequence once. 7

Limit use to ≤ 3–5 consecutive days to avoid rhinitis medicamentosa (rebound congestion) and mucosal damage that can provoke further epistaxis. 8, 9, 10
Avoid in patients with uncontrolled hypertension because systemic vasoconstriction may precipitate cardiovascular complications. 7
Use with caution in patients with cardiovascular disease due to increased risk of systemic adverse effects. 8
Use with caution in patients with glaucoma because of potential systemic vasoconstrictive complications. 9

After hemostasis, switch immediately to nasal saline spray or gel applied 2–4 times daily to maintain mucosal moisture; this reduces recurrent epistaxis in up to 65 % of cases. 7

Seek emergency care if bleeding continues after two attempts of oxymetazoline plus compression, or if the patient experiences weakness, light‑headedness, dizziness, severe bleeding, or breathing difficulty. 7

Do not check for cessation before 5 minutes; premature release of compression is a leading cause of treatment failure. 7
Do not use oxymetazoline prophylactically; it is intended only for active bleeding, followed by saline moisturization. 10
Do not walk away after spraying; maintain continuous compression for the full 5–10 minutes. 7
Do not tilt the head back; this directs blood toward the throat and does not aid hemostasis. 7